Abbott Laboratories ABT.N:
ABBOTT -DEAL EXPECTED TO BE DILUTIVE TO ADJUSTED EARNINGS PER SHARE THROUGH 2027- SEC FILING
ABBOTT: EXACT SCIENCES TO PAY OR CAUSE TO BE PAID BY A U.S. PERSON TO ABBOTT $628.7 MILLION IF DEAL IS TERMINATED UNDER SOME CIRCUMSTANCES - SEC FILING
Source text: [ID:n0001104659-25-114422]
Further company coverage: ABT.N
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.